This effect has further been examined and proven in acquired BRAF mutation inhibitor resistance moles, which were shown to have a reduction in tumor volume when analyzed in in vivo melanoma models for both BRAF mutation positive and negative xenografts. The gene discussed is BRAF; the disease is melanoma.